Tempus expands further into revolutionizing cardiovascular disease care
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced the acquisition of Mpirik, a cardiology-focused healthcare technology company specializing in data-driven patient screening, automated care coordination, and clinical research. The combination of Mpirik’s Cardiac Intelligence® platform with Tempus’ AI-enabled precision medicine solutions will accelerate the company’s mission to identify patients with undiagnosed and undertreated cardiovascular disease. Integrating Mpirik’s Cardiac Intelligence® software into the Tempus platform enables a comprehensive solution for the way heart disease is detected, diagnosed and treated.
Today, millions of patients suffer from heart disease yet remain undiagnosed because they have not had the appropriate clinical evaluation. Tempus is using state-of-the-art AI algorithms on routinely collected clinical data to build next generation diagnostics designed to find these patients earlier, when treatments are most effective. Even when patients are diagnosed efficiently, more than 50% do not receive guideline-recommended therapies proven to prolong life and reduce suffering. Mpirik’s Cardiac Intelligence® software addresses this problem by reviewing health record data, identifying patients with any of 60 potential treatment gaps, and routing them to a clinician for further evaluation and treatment.
“The acquisition of Mpirik further solidifies our position as a leader in AI-enabled precision medicine, and doubles down on our commitment to helping cardiologists fight the number one killer worldwide – heart disease,” said Eric Lefkofsky, Founder and CEO of Tempus. “This represents an important step forward to help the estimated hundreds of thousands of U.S. residents who die unnecessarily each year from heart disease and stroke as a result of underdiagnosis or undertreatment.”
“We look forward to integrating the advanced AI capabilities of Tempus into our software platform that is already operating at scale at health systems throughout the U.S.,” said Logan Brigman, CEO of Mpirik “This network of providers is hungry for data-driven solutions to continue to improve patient outcomes through the early identification and treatment of cardiovascular disease.”
Tempus’ AI-enabled precision medicine platform, Tempus Air™, aims to facilitate more timely diagnosis and treatment of disease by layering algorithms on top of clinical data, such as an electrocardiogram (ECG). In 2021, the U.S. Food and Drug Administration granted Tempus Breakthrough Device Designation for its risk predictor that aids clinicians in identifying patients at increased risk of developing AFib, which is currently being used in a multi-center, prospective study, titled ECG-AID, along with Tempus’ structural heart disease predictive algorithm.
To learn more about Tempus’ cardiology work, visit www.tempus.com/cardiology.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.